---
title: "Foundayo (orforglipron) in chronic weight management: Clinical trials questions"
description: "Clinical trials questions on Foundayo (orforglipron) in chronic weight management, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results and Subgroup results. Questions: Does Foundayo reduce fat mass more than lean mass? What was the Foundayo ATTAIN-1 trial design? What was the Foundayo ATTAIN-2 trial design in type 2 diabetes? How much weight did adults without diabetes lose on Foundayo vs placebo (ATTAIN-1)? 9 further questions follow. 13 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Foundayo (orforglipron) in chronic weight management: Clinical trials questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Foundayo](https://uspl.lilly.com/foundayo/foundayo.html#pi)

## Study results

<a id="foundayo-fat-vs-lean-mass"></a>

### Does Foundayo reduce fat mass more than lean mass?

> “FOUNDAYO reduces body weight, with greater fat mass loss than lean mass loss.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=FOUNDAYO%20reduces%20body%20weight%2C%20with,loss%20than%20lean%20mass%20loss.)

Note: This passage is from the Pharmacodynamics section of the Prescribing Information. The home page of the Foundayo HCP site describes a body composition (DXA) substudy, but its captured text gives no fat mass or lean mass results.

<a id="foundayo-attain1-weight-loss"></a>

### How much weight did adults without diabetes lose on Foundayo vs placebo (ATTAIN-1)?

Applies to: Adults with obesity, or with overweight and at least one weight-related comorbid condition, without type 2 diabetes (ATTAIN-1; Trial 1 in the Prescribing Information)

> “Bar chart shows the percent change in body weight from baseline at 72 weeks for Foundayo 5.5 mg, 9 mg, 17.2 mg, and placebo. There were 723, 725, 730, and 949 total adults given Foundayo 5.5 mg, 9 mg, 17.2 mg, and placebo, respectively. The percent change in body weight at 72 weeks was -7.4% for Foundayo 5.5 mg, -8.3% for Foundayo 9 mg, -11.1% for Foundayo 17.2 mg, and -2.1% for placebo. The change in body weight from baseline at 72 weeks was -17.2 lb for Foundayo 5.5 mg, -18.9 lb for Foundayo 9 mg, -24.9 lb for Foundayo 17.2 mg, and -5.3 lb for placebo. Mean baseline body weight was 227.5 lb for Foundayo 5.5 mg, 225.3 lb for Foundayo 9 mg, 227.3 lb for Foundayo 17.2 mg, and 229.1 lb for placebo.”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Bar%20chart%20shows%20the%20percent,and%20229.1%20lb%20for%20placebo.)

On the page, select: Show description

> “The primary endpoint was mean percent change in body weight: P<0.001 for superiority of Foundayo vs placebo.<sup>1,3</sup> An additional secondary endpoint not controlled for Type 1 error was mean absolute change in body weight (lb).<sup>3</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=The%20primary%20endpoint%20was%20mean,absolute%20change%20in%20body%20weight)

> “Studied in adults with obesity (BMI ≥30 kg/m<sup>2</sup>), or with overweight (BMI 27 to <30 kg/m<sup>2</sup>) with at least one weight-related comorbidity, excluding diabetes.<sup>1,3</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Studied%20in%20adults%20with%20obesity,least%20one%20weight%2Drelated%20comorbidity%2C%20excluding)

> “Treatment and placebo included a reduced-calorie diet and increased physical activity.<sup>1</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Treatment%20and%20placebo%20included%20a%20reduced%2Dcalorie%20diet%20and%20increased%20physical)

> “This trial was done using an investigational formulation of orforglipron at dosages equivalent to once-daily Foundayo.<sup>1</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=This%20trial%20was%20done%20using,at%20dosages%20equivalent%20to%20once%2Ddaily)

> “ITT population includes all randomized patients. Missing data were imputed from retrieved patients of the same randomized treatment group when the missingness was possibly related to study treatment; otherwise, missing data were imputed using observed data from the same randomized treatment group. Unconditional average treatment effect estimated using ANCOVA adjusted for baseline value and other stratification factors.<sup>1</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=ITT%20population%20includes%20all%20randomized,baseline%20value%20and%20other%20stratification)

> “The proportions of patients who discontinued treatment in ATTAIN-1 were 22%, 22%, and 24% for the 5.5 mg, 9 mg, and 17.2 mg once daily Foundayo-treated groups, respectively, and 30% for the placebo-treated group.<sup>1</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=The%20proportions%20of%20patients%20who,and%2030%25%20for%20the%20placebo%2Dtreated)

Note: The values are from the figure description on the clinical data page of the Foundayo HCP site; Table 6 of the Prescribing Information gives the same percent changes with each difference from placebo and its 95% CI.

<a id="foundayo-attain2-weight-loss"></a>

### How much weight did adults with type 2 diabetes lose on Foundayo vs placebo (ATTAIN-2)?

Applies to: Adults with obesity or overweight (BMI 27 kg/m2 or greater) and type 2 diabetes (ATTAIN-2; Trial 2 in the Prescribing Information)

> “In a separate weight-reduction study of adults with a BMI ≥27 kg/m<sup>2</sup> and type 2 diabetes, the overall percentage change in body weight from baseline at 72 weeks was -5.1% (5.5 mg), -7.0% (9 mg), -9.6% (17.2 mg), and -2.5% for placebo.<sup>1</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=In%20a%20separate%20weight%2Dreduction%20study,%2817.2%20mg%29%2C%20and%20%2D2.5%25%20for)

> “For Trials 1 and 2, the primary efficacy parameter was mean percent change in body weight from baseline to Week 72. After 72 weeks of treatment in Trials 1 and 2, there was a statistically significant reduction in body weight in the FOUNDAYO-treated groups compared with the placebo groups (see Table 6). A reduction in body weight was observed with FOUNDAYO regardless of age, sex, race, ethnicity, baseline BMI, and glycemic status.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=For%20Trials%201%20and%202%2C,baseline%20BMI%2C%20and%20glycemic%20status.)

> “The proportions of patients who discontinued treatment in ATTAIN-2 were 19%, 22%, and 20% for the 5.5 mg, 9 mg, and 17.2 mg once daily Foundayo-treated groups, respectively, and 20% for the placebo-treated group.<sup>1</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=The%20proportions%20of%20patients%20who%20discontinued%20treatment%20in%20ATTAIN%2D2,and%2020%25%20for%20the%20placebo%2Dtreated)

> “This section of labeling presents efficacy data from administration of the investigational orforglipron formulation shown as equivalent dosages of once daily FOUNDAYO [see Dosage and Administration (2.1)].”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=This%20section%20of%20labeling%20presents%20efficacy,%5Bsee%20Dosage%20and%20Administration%20%282.1%29%5D.)

Note: The clinical data page of the Foundayo HCP site names the trials ATTAIN-1 and ATTAIN-2, and gives the pooled figures of the label's Trials 1 and 2 under those names (for example, "In a pool of 2 Foundayo clinical studies for weight reduction (ATTAIN-1 and ATTAIN-2), 399 (13%)" patients were 65 or older). The Prescribing Information reports the same enrollment (3,127 and 1,613 adults) under the names Trial 1 and Trial 2. Table 6 of the Prescribing Information gives each difference from placebo with its 95% CI.

<a id="foundayo-weight-loss-thresholds"></a>

### What share of patients lost 10% or more of body weight on Foundayo?

> “Table 6: Changes from Baseline in Body Weight at Week 72 in Trials 1 and 2 in Patients with Obesity or Overweight with ≥1 Weight-related Comorbid Condition
>
> Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to trial drug.
>
> Note: Baseline mean is calculated using all randomized patients.
>
>
>
>
> a The intent-to-treat population consists of all randomized patients. For Trial 1 at Week 72, the body weight endpoint was missing for 24%, 16%, 14%, and 15% of patients randomized to placebo, FOUNDAYO 5.5 mg once daily, 9 mg once daily and 17.2 mg once daily, respectively. For Trial 2 at Week 72, the body weight endpoint was missing for 13%, 13%, 10%, and 7% of patients randomized to placebo, FOUNDAYO 5.5 mg once daily, 9 mg once daily and 17.2 mg once daily, respectively. Missing data were imputed from retrieved patients of the same randomized treatment group when the missingness was possibly related to trial treatment; otherwise, missing data were imputed using observed data from the same randomized treatment group (primary modified multiple imputation).
>
>
>
>
> b Unconditional average treatment effect estimated using ANCOVA adjusted for baseline value and other stratification factors.
>
>
>
>
> c p<0.001 (unadjusted 2-sided) compared to placebo for superiority; controlled for multiplicity.
>
>
>
>
> d Unconditional average treatment effect estimated using logistic regression adjusted for baseline value and other stratification factors.
>
>
>
>
> e Not controlled for multiplicity.
>
>
> 	Trial 1 (without diabetes)	Trial 2 (with type 2 diabetes)
> Intent-to-Treat (ITT) Populationa	Placebo
> once daily
> N = 949	FOUNDAYO
> 5.5 mg
> once daily
> N = 723	FOUNDAYO
> 9 mg
> once daily
> N = 725	FOUNDAYO
> 17.2 mg
> once daily
> N = 730	Placebo
> once daily
> N = 630	FOUNDAYO
> 5.5 mg
> once daily
> N = 329	FOUNDAYO
> 9 mg
> once daily
> N = 332	FOUNDAYO
> 17.2 mg
> once daily
> N = 322
> Body Weight								
> Baseline mean (kg)	103.9	103.2	102.2	103.1	101.2	102.3	102.7	99.8
> % Change from baselineb	-2.1	-7.4	-8.3	-11.1	-2.5	-5.1	-7	-9.6
> % difference from placebo (95% CI)b		-5.3
> (-6.1, -4.4)c	-6.2
> (-7.1, -5.3)c	-9
> (-10, -8.1)c		-2.6
> (-3.5, -1.6)c	-4.5
> (-5.4, -3.6)c	-7.1
> (-8.1, -6.1)c
> % of patients who lost ≥5% body weight	26.8	59.6	63.1	71.5	26.8	47.4	54.7	67
> % difference from placebo (95% CI)d		32.7
> (27.9, 37.6)c	36.3
> (31.5, 41.1)c	44.7
> (40, 49.3)c		20.6
> (13.9, 27.3)c	27.9
> (21.3, 34.5)c	40.2
> (33.8, 46.6)c
> % of patients who lost ≥10% body weight	13	32.5	39.8	54.5	9.2	22.5	31.1	45.6
> % difference from placebo (95% CI)d		19.4
> (15.1, 23.7)c	26.8
> (22.4, 31.1)c	41.4
> (37, 45.9)c		13.3
> (8.1, 18.5)c	21.9
> (16.3, 27.5)c	36.4
> (30.5, 42.3)c
> % of patients who lost ≥15% body weight	6	14.3	20.1	35.9	3.1	6.7	14.4	25.9
> % difference from placebo (95% CI)d		8.3
> (5.2, 11.4)c	14.1
> (10.7, 17.6)c	29.8
> (25.9, 33.7)c		3.6
> (0.4, 6.8)e	11.3
> (7.3, 15.3)c	22.8
> (17.8, 27.8)c
> % of patients who lost ≥20% body weight	2.9	5.9	8.9	18.4	0.7	2.6	4.4	10.8
> % difference from placebo (95% CI)d		3
> (0.9, 5.2)e	6
> (3.5, 8.4)c	15.5
> (12.4, 18.6)c		1.8
> (-0.2, 3.8)e	3.7
> (1.4, 6)e	10.1
> (6.6, 13.5)e”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Table%206%3A%20Changes%20from%20Baseline,%286.6%2C%2013.5%29e)

> “This section of labeling presents efficacy data from administration of the investigational orforglipron formulation shown as equivalent dosages of once daily FOUNDAYO [see Dosage and Administration (2.1)].”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=This%20section%20of%20labeling%20presents%20efficacy,%5Bsee%20Dosage%20and%20Administration%20%282.1%29%5D.)

Note: Columns are Trial 1 (without diabetes) placebo, FOUNDAYO 5.5 mg, 9 mg, and 17.2 mg, then Trial 2 (with type 2 diabetes) placebo, FOUNDAYO 5.5 mg, 9 mg, and 17.2 mg, as in the table header. In each "difference from placebo" row the placebo cells are empty. The table also gives the shares of patients who lost at least 5%, 15%, and 20% of body weight. The clinical data page of the Foundayo HCP site names the trials ATTAIN-1 and ATTAIN-2, and gives the pooled figures of the label's Trials 1 and 2 under those names (for example, "In a pool of 2 Foundayo clinical studies for weight reduction (ATTAIN-1 and ATTAIN-2), 399 (13%)" patients were 65 or older). The Prescribing Information reports the same enrollment (3,127 and 1,613 adults) under the names Trial 1 and Trial 2.

<a id="foundayo-weight-loss-subgroups"></a>

### Did Foundayo reduce body weight across age, sex, race, and BMI subgroups?

> “A reduction in body weight was observed with FOUNDAYO regardless of age, sex, race, ethnicity, baseline BMI, and glycemic status.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=A%20reduction%20in%20body%20weight,baseline%20BMI%2C%20and%20glycemic%20status.)

<a id="foundayo-waist-circumference"></a>

### How much does Foundayo reduce waist circumference (ATTAIN-1)?

Applies to: Adults with obesity, or with overweight and at least one weight-related comorbid condition, without type 2 diabetes (ATTAIN-1; Trial 1 in the Prescribing Information)

> “The table shows the mean reduction in waist circumference from baseline to 72 weeks for Foundayo 5.5 mg, 9 mg, 17.2 mg, and placebo. There were 723, 725, 730, and 949 total adults for Foundayo 5.5 mg, 9 mg, 17.2 mg, and placebo, respectively. The mean baseline waist circumference was 44.2 inches for Foundayo 5.5 mg, 44.1 inches for Foundayo 9 mg, 44.3 inches for Foundayo 17.2 mg, and 44.4 inches for placebo. Reduction was -2.8 inches for Foundayo 5.5 mg, -3.2 inches for Foundayo 9 mg, -3.9 inches for Foundayo 17.2 mg, and -1.2 inches for placebo.”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=The%20table%20shows%20the%20mean,and%20%2D1.2%20inches%20for%20placebo.)

On the page, select: Table description

> “Key secondary endpoint: P<0.001 for superiority of Foundayo vs placebo.<sup>1,3</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Key%20secondary%20endpoint%3A%20P%3C0.001%20for%20superiority%20of%20Foundayo%20vs)

> “This trial was done using an investigational formulation of orforglipron at dosages equivalent to once-daily Foundayo.<sup>1</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=This%20trial%20was%20done%20using%20an%20investigational%20formulation%20of%20orforglipron%20at%20dosages%20equivalent%20to%20once%2Ddaily%20Foundayo.1,-Key%20secondary%20endpoint%3A)

Note: Table 7 of the Prescribing Information gives the same results in centimeters for Trial 1 and Trial 2, with each difference from placebo and its 95% CI.

<a id="foundayo-blood-pressure-lipids"></a>

### Does Foundayo lower blood pressure and triglycerides (ATTAIN-1 and ATTAIN-2)?

> “Table 7: Changes from Baseline Anthropometry and Cardiometabolic Parameters at Week 72 in Trials 1 and 2 in Patients with Obesity or Overweight with ≥1 Weight-related Comorbid Condition”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Table%207%3A%20Changes%20from%20Baseline,with%20%E2%89%A51%20Weight%2Drelated%20Comorbid%20Condition)

> “Systolic Blood Pressure (mm Hg)
> Baseline mean	125.8	125.4	125.1	125.8	130.6	131.3	132.1	132.5
> Change from baselineb	-1.4	-5.7	-5.1	-6.4	-1.5	-4	-4.2	-4.6
> Difference from placebo (95% CI)b		-4.2
> (-5.4, -3)d	-3.7
> (-4.8, -2.5)d	-4.9
> (-6.1, -3.8)d		-2.5
> (-4.1, -0.8)d	-2.7
> (-4.4, -1)d	-3
> (-4.8, -1.2)d”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Systolic%20Blood%20Pressure%20%28mm%20Hg%29,%28%2D4.8%2C%20%2D1.2%29d)

> “Triglycerides (mg/dL)
> Baseline meane	125.3	121.1	119.2	125.6	162.4	157.8	164.4	157.2
> Percent change from baselineb	-4	-10.4	-13.1	-20	-4.1	-13.3	-14.7	-19.4
> Relative difference from placebo (95% CI)b		-6.7
> (-9.9, -3.3)d,f	-9.4
> (-12.6,
> -6.1)d,f	-16.6
> (-19.5,
> -13.6)d,f		-9.6
> (-14.5, -4.4)d,f	-11
> (-15.6,
> -6.2)d,f	-15.9
> (-20.3,
> -11.3)d,f”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Triglycerides%20%28mg%2FdL%29,%2D11.3%29d%2Cf)

> “d Not controlled for multiplicity.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=d%20Not%20controlled%20for%20multiplicity.)

> “f Analyzed using log-transformed data.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=f%20Analyzed%20using%20log%2Dtransformed%20data.)

> “The graphic shows that cardiometabolic measures controlled for type I error rate included triglycerides and systolic blood pressure. Triglycerides were reduced by 14.8% with Foundayo vs 3.8% with placebo. The mean baseline for triglycerides was 122.0 mg/dL for Foundayo and 125.4 mg/dL for placebo. Systolic blood pressure was reduced by 5.7 mmHg with Foundayo vs 1.4 mmHg with placebo. The mean baseline systolic blood pressure was 125.4 mmHg for Foundayo and 125.8 mmHg for placebo. Cardiometabolic measures not controlled for type I error included LDL cholesterol, HDL cholesterol, and diastolic blood pressure. LDL cholesterol was reduced by 4.8% with Foundayo vs 1.3% with placebo. The mean baseline LDL cholesterol was 114.3 mg/dL for Foundayo and 114.3 mg/dL for placebo. HDL cholesterol increased by 3.2% with Foundayo vs a reduction of 0.9% with placebo. The mean baseline HDL cholesterol was 47.9 mg/dL for Foundayo and 47.7 mg/dL for placebo. Diastolic blood pressure was reduced by 2.4 mmHg with Foundayo vs 1.4 mmHg with placebo. The mean baseline diastolic blood pressure was 81.0 mmHg for Foundayo and 81.8 mmHg for placebo. Foundayo is not indicated for hypertension or dyslipidemia.”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=The%20graphic%20shows%20that%20cardiometabolic,indicated%20for%20hypertension%20or%20dyslipidemia.)

On the page, select: Show description

> “Key secondary endpoints included percent change in triglycerides and change in systolic blood pressure: P<0.001 for superiority of pooled Foundayo vs placebo.<sup>3</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Key%20secondary%20endpoints%20included%20percent,superiority%20of%20pooled%20Foundayo%20vs)

> “Results may vary by dose.”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Results%20may%20vary%20by%20dose.)

> “This trial was done using an investigational formulation of orforglipron at dosages equivalent to once-daily Foundayo.<sup>1</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=of%2073.7%20beats%2Fminute.3-,This%20trial%20was%20done%20using%20an%20investigational%20formulation%20of%20orforglipron,dosages%20equivalent%20to%20once%2Ddaily%20Foundayo.1)

Note: Columns are Trial 1 (without diabetes) placebo, FOUNDAYO 5.5 mg, 9 mg, and 17.2 mg, then Trial 2 (with type 2 diabetes) placebo, FOUNDAYO 5.5 mg, 9 mg, and 17.2 mg, as in the table header. In each "difference from placebo" row the placebo cells are empty. The Prescribing Information is the governing source. Its Table 7 gives each dose separately for Trial 1 (ATTAIN-1) and Trial 2 (ATTAIN-2) and marks every systolic blood pressure and triglyceride difference from placebo, in both trials, with footnote d, "Not controlled for multiplicity." The clinical data page of the Foundayo HCP site gives pooled results for Foundayo 5.5 mg, 9 mg, and 17.2 mg in ATTAIN-1, cites the ATTAIN-1 publication (Wharton et al., N Engl J Med 2025), and describes triglycerides and systolic blood pressure as controlled for type I error with P<0.001 for superiority of pooled Foundayo. The two sources report different analyses (pooled doses against each dose) and differ on multiplicity control.

<a id="foundayo-a1c-type-2-diabetes"></a>

### How much did Foundayo lower A1C in adults with type 2 diabetes (ATTAIN-2)?

Applies to: Adults with obesity or overweight (BMI 27 kg/m2 or greater) and type 2 diabetes (ATTAIN-2; Trial 2 in the Prescribing Information)

> “HbA1c (%)
> Baseline mean	5.6	5.6	5.6	5.6	8	8	8.1	8.1
> Change from baselineb	-0.1	-0.3	-0.3	-0.3	-0.4	-1.2	-1.4	-1.7
> Difference from placebo (95% CI)b		-0.2
> (-0.2, -0.2)d	-0.2
> (-0.2, -0.2)d	-0.3
> (-0.3, -0.2)d		-0.8
> (-1, -0.6)c	-1
> (-1.2, -0.8)c	-1.2
> (-1.4, -1.1)c”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=%282%2C%204.4%29d-,HbA1c,%28%2D1.4%2C%20%2D1.1%29c)

> “Some key secondary endpoints were percentage of participants who achieved ≥5% and ≥10% body weight reduction on Foundayo 5.5 mg; percentage of participants who achieved ≥5%, ≥10%, and ≥15% body weight reduction on Foundayo 9 mg or 17.2 mg; mean change in A1C (%); percentage of participants who achieved A1C <7.0%; and mean change in fasting glucose.<sup>1,7</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Some%20key%20secondary%20endpoints%20were,and%20mean%20change%20in%20fasting)

> “Table 7: Changes from Baseline Anthropometry and Cardiometabolic Parameters at Week 72 in Trials 1 and 2 in Patients with Obesity or Overweight with ≥1 Weight-related Comorbid Condition”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Table%207%3A%20Changes%20from%20Baseline,with%20%E2%89%A51%20Weight%2Drelated%20Comorbid%20Condition)

> “This section of labeling presents efficacy data from administration of the investigational orforglipron formulation shown as equivalent dosages of once daily FOUNDAYO [see Dosage and Administration (2.1)].”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=This%20section%20of%20labeling%20presents%20efficacy,%5Bsee%20Dosage%20and%20Administration%20%282.1%29%5D.)

Note: Columns are Trial 1 (without diabetes) placebo, FOUNDAYO 5.5 mg, 9 mg, and 17.2 mg, then Trial 2 (with type 2 diabetes) placebo, FOUNDAYO 5.5 mg, 9 mg, and 17.2 mg, as in the table header. In each "difference from placebo" row the placebo cells are empty. The last four columns are Trial 2 (adults with type 2 diabetes). Footnote c marks p<0.001 compared to placebo, controlled for multiplicity; footnote d marks results not controlled for multiplicity. The labeled indication of Foundayo is weight reduction and maintenance.

## Clinical trials

<a id="foundayo-attain1-design"></a>

### What was the Foundayo ATTAIN-1 trial design?

Applies to: Adults with obesity, or with overweight and at least one weight-related comorbid condition, without type 2 diabetes (ATTAIN-1; Trial 1 in the Prescribing Information)

> “ATTAIN-1 was a randomized, double-blind, placebo-controlled, phase 3 trial that enrolled 3,127 adult patients with a body mass index (BMI) ≥30 kg/m<sup>2</sup>, or a BMI 27 to <30 kg/m<sup>2</sup> and at least one weight-related comorbid condition (patients with diabetes excluded). Treatment was an adjunct to a reduced-calorie diet and increased physical activity.* Mean baseline body weight was 227.5 lb for 5.5 mg, 225.3 lb for 9 mg, 227.3 lb for 17.2 mg, and 229.1 lb for placebo.<sup>1,3</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=ATTAIN%2D1%20was%20a%20randomized%2C%20double%2Dblind%2C,mg%2C%20and%20229.1%20lb%20for)

> “Graphic of the ATTAIN-1 study design. After a 3-week screening period, participants (N=3127) were randomly assigned in a 3:3:3:4 ratio to receive once-daily Foundayo 5.5 mg, 9 mg, or 17.2 mg, or placebo for 72 weeks (primary endpoint) that included a dose-escalation period of up to 20 weeks. All participants initiated treatment with a 0.8 mg daily dose of Foundayo or matching placebo. The dose of Foundayo was increased every 4 weeks until the randomized assigned dose of either 5.5 mg, 9 mg, or 17.2 mg was reached. For the 5.5 mg dose, participants received each of the following escalating doses for 4 weeks: 0.8 mg and 2.5 mg. At week 8, participants reached the assigned dose of 5.5 mg. For the 9 mg dose, participants received each of the following escalating doses for 4 weeks: 0.8 mg, 2.5 mg, and 5.5 mg. At week 12, participants reached the assigned dose of 9 mg. For the 17.2 mg dose, participants received each of the following escalating doses for 4 weeks: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, and 14.5 mg. At week 20, participants reached the assigned dose of 17.2 mg. All treatment arms and placebo were in adjunct to a reduced-calorie diet and increased physical activity.”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Graphic%20of%20the%20ATTAIN%2D1%20study,diet%20and%20increased%20physical%20activity.)

On the page, select: Show description

> “The primary endpoint was mean percent change in body weight from baseline to week 72.<sup>1,3</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=The%20primary%20endpoint%20was%20mean%20percent%20change%20in%20body%20weight%20from%20baseline,-to%20week)

> “Some key secondary endpoints assessed at 72 weeks: superiority of Foundayo 5.5 mg, 9 mg, and 17.2 mg to placebo for percentage of patients who achieved body weight reduction of ≥5%, ≥10%, ≥15%, or ≥20%.<sup>1,3</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Some%20key%20secondary%20endpoints%20assessed,of%20%E2%89%A55%25%2C%20%E2%89%A510%25%2C%20%E2%89%A515%25%2C%20or)

> “*Minimum recommended physical activity was 150 minutes/week.<sup>1</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=%2AMinimum%20recommended%20physical%20activity%20was%20150)

> “This trial was done using an investigational formulation of orforglipron at dosages equivalent to once-daily Foundayo.<sup>1</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=%E2%89%A515%25%2C%20or%20%E2%89%A520%25.1%2C3-,This%20trial%20was%20done%20using%20an%20investigational%20formulation%20of%20orforglipron,dosages%20equivalent%20to%20once%2Ddaily%20Foundayo.1)

Note: The clinical data page of the Foundayo HCP site names the trials ATTAIN-1 and ATTAIN-2, and gives the pooled figures of the label's Trials 1 and 2 under those names (for example, "In a pool of 2 Foundayo clinical studies for weight reduction (ATTAIN-1 and ATTAIN-2), 399 (13%)" patients were 65 or older). The Prescribing Information reports the same enrollment (3,127 and 1,613 adults) under the names Trial 1 and Trial 2.

<a id="foundayo-attain2-design"></a>

### What was the Foundayo ATTAIN-2 trial design in type 2 diabetes?

Applies to: Adults with obesity or overweight (BMI 27 kg/m2 or greater) and type 2 diabetes (ATTAIN-2; Trial 2 in the Prescribing Information)

> “ATTAIN-2 was a randomized, double-blind, placebo-controlled, phase 3 trial that enrolled 1613 adult patients with a body mass index (BMI) ≥27 kg/m<sup>2</sup> and type 2 diabetes. Patients included in the trial had baseline A1C 7% to 10% and had stable treatment for type 2 diabetes with either diet and exercise alone, or any oral anti-hyperglycemic agent except DPP-4 inhibitors or GLP-1 receptor agonists. Treatment was an adjunct to a reduced-calorie diet and increased physical activity.* Mean baseline body weight was 225.5 lb (5.5 mg), 226.4 lb (9 mg), 220.0 lb (17.2 mg), and 223.1 lb for placebo.<sup>1,7</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=ATTAIN%2D2%20was%20a%20randomized%2C%20double%2Dblind%2C,mg%29%2C%20and%20223.1%20lb%20for)

> “Graphic of the ATTAIN-2 study design. After a 3-week screening period, participants (N=1613) were randomly assigned in a 1:1:1:2 ratio to receive once-daily Foundayo 5.5 mg, 9 mg, and 17.2 mg doses, respectively or placebo for 72 weeks that included a dose-escalation period of up to 20 weeks. All participants initiated treatment with a 0.8 mg daily dose of Foundayo or matching placebo. The dose of Foundayo was increased every 4 weeks until the randomized assigned dose of 5.5 mg, 9 mg, or 17.2 mg was reached. For the 5.5 mg dose, participants received each of the following escalating doses for 4 weeks: 0.8 mg and 2.5 mg. At week 8, participants reached the assigned dose of 5.5 mg. For the 9 mg dose, participants received each of the following escalating doses for 4 weeks: 0.8 mg, 2.5 mg, and 5.5 mg. At week 12, participants reached the assigned dose of 9 mg. For the 17.2 mg dose, participants received each of the following escalating doses for 4 weeks: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, and 14.5 mg. At week 20, participants reached the assigned dose of 17.2 mg. All treatment arms and placebo were in adjunct to a reduced-calorie diet and increased physical activity.”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Graphic%20of%20the%20ATTAIN%2D2%20study,diet%20and%20increased%20physical%20activity.)

On the page, select: Show description

> “The primary endpoint was mean percent change in body weight from baseline to week 72.<sup>1,7</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=lb%20for%20placebo.1%2C7-,The%20primary%20endpoint%20was%20mean%20percent%20change%20in%20body%20weight,from%20baseline%20to%20week%2072.1%2C7)

> “Some key secondary endpoints were percentage of participants who achieved ≥5% and ≥10% body weight reduction on Foundayo 5.5 mg; percentage of participants who achieved ≥5%, ≥10%, and ≥15% body weight reduction on Foundayo 9 mg or 17.2 mg; mean change in A1C (%); percentage of participants who achieved A1C <7.0%; and mean change in fasting glucose.<sup>1,7</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Some%20key%20secondary%20endpoints%20were,and%20mean%20change%20in%20fasting)

> “This trial was done using an investigational formulation of orforglipron at dosages equivalent to once-daily Foundayo.<sup>1</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=in%20fasting%20glucose.1%2C7-,This%20trial%20was%20done%20using%20an%20investigational%20formulation%20of%20orforglipron,dosages%20equivalent%20to%20once%2Ddaily%20Foundayo.1)

Note: The clinical data page of the Foundayo HCP site names the trials ATTAIN-1 and ATTAIN-2, and gives the pooled figures of the label's Trials 1 and 2 under those names (for example, "In a pool of 2 Foundayo clinical studies for weight reduction (ATTAIN-1 and ATTAIN-2), 399 (13%)" patients were 65 or older). The Prescribing Information reports the same enrollment (3,127 and 1,613 adults) under the names Trial 1 and Trial 2.

## Subgroup results

<a id="foundayo-bmi-subgroup"></a>

### How much weight did patients with BMI under 35 lose on Foundayo (ATTAIN-1 and ATTAIN-2)?

> “Bar chart shows the percent change in body weight from baseline at week 72 for patients with a baseline BMI of <30 kg/m² or ≥30 kg/m² to <35 kg/m² treated with Foundayo 5.5 mg, 9 mg, and 17.2 mg and placebo. The percent change in body weight at 72 weeks for patients with a baseline BMI of <30 kg/m² was -6.3% for Foundayo 5.5 mg (n=62), -8.9% for Foundayo 9 mg (n=72), -12.5% for Foundayo 17.2 mg (n=68), and -0.5% for placebo (n=86). The percent change in body weight at 72 weeks for patients with a baseline BMI of ≥30 kg/m² to <35 kg/m² was -7.6% for Foundayo 5.5 mg (n=263), -8.4% for Foundayo 9 mg (n=272), -11.1% for Foundayo 17.2 mg (n=285), and -1.6% for placebo (n=331).”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Bar%20chart%20shows%20the%20percent%20change%20in%20body%20weight%20from%20baseline%20at,-week%2072%20for)

On the page, select: Show description

> “Study Limitations: This was a prespecified subgroup analysis not adjusted for type I error. Subgroup sample sizes are limited; therefore, findings should be interpreted with caution.<sup>3</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Study%20Limitations%3A%20This%20was%20a,findings%20should%20be%20interpreted%20with)

> “In ATTAIN-2, placebo-adjusted percent change from baseline in body weight at week 72 for baseline BMI <30 kg/m² were -3.12% (5.5 mg), -4.19% (9 mg), and -6.12% (17.2 mg); for BMI 30 to <35 kg/m², differences were -2.27% (5.5 mg), -4.73% (9 mg), and -7.90% (17.2 mg).<sup>7</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=In%20ATTAIN%2D2%2C%20placebo%2Dadjusted%20percent%20change,%289%20mg%29%2C%20and%20%2D7.90%25%20%2817.2)

> “This trial was done using an investigational formulation of orforglipron at dosages equivalent to once-daily Foundayo.<sup>1</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=increased%20physical%20activity.1-,This%20trial%20was%20done%20using%20an%20investigational%20formulation%20of%20orforglipron,dosages%20equivalent%20to%20once%2Ddaily%20Foundayo.1)

> “Foundayo is not indicated for cosmetic weight loss.”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Show%20description-,Foundayo%20is%20not%20indicated%20for%20cosmetic%20weight%20loss.)

Note: The third passage gives ATTAIN-2 results as differences from placebo; the figure description gives ATTAIN-1 percent changes for each group.

<a id="foundayo-menopause-subgroup"></a>

### How much weight did women lose on Foundayo by menopausal stage (ATTAIN-1, post hoc)?

Applies to: Adults with obesity, or with overweight and at least one weight-related comorbid condition, without type 2 diabetes (ATTAIN-1; Trial 1 in the Prescribing Information)

> “Weight reduction was observed in women treated with Foundayo across all menopausal stages at week 72<sup>8,9</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Weight%20reduction%20was%20observed%20in%20women,all%20menopausal%20stages%20at%20week)

> “Bar chart shows the percent change in body weight by menopausal stage from baseline to 72 weeks for Foundayo 5.5 mg, 9 mg, and 17.2 mg tablets, and placebo. In the premenopause group for Foundayo 5.5 mg, there were 154 women with a mean baseline weight of 221.6 lb and a 7.4% reduction in body weight from baseline. For Foundayo 9 mg, there were 161 women with a mean baseline weight of 225.1 lb and an 8.3% reduction in body weight from baseline. For Foundayo 17.2 mg, there were 171 women with a mean baseline weight of 219.2 lb and a 12.0% reduction in body weight from baseline. For placebo, there were 225 women with a mean baseline weight of 217.4 lb and a 2.4% reduction in body weight from baseline. In the perimenopause group for Foundayo 5.5 mg, there were 158 women with a mean baseline weight of 214.5 lb and an 8.3% reduction in body weight from baseline. For Foundayo 9 mg, there were 137 women with a mean baseline weight of 210.5 lb and an 10.8% reduction in body weight from baseline. For Foundayo 17.2 mg, there were 142 women with a mean baseline weight of 217.5 lb and a 13.1% reduction in body weight from baseline. For placebo, there were 189 women with a mean baseline weight of 218.9 lb and a 2.3% reduction in body weight from baseline. In the postmenopause group for Foundayo 5.5 mg, there were 154 women with a mean baseline weight of 211.4 lb and an 8.9% reduction in body weight from baseline. For Foundayo 9 mg, there were 168 women with a mean baseline weight of 209.0 lb and a 10.0% reduction in body weight from baseline. For Foundayo 17.2 mg, there were 152 women with a mean baseline weight of 208.6 lb and a 12.6% reduction in body weight from baseline. For placebo, there were 192 women with a mean baseline weight of 211.7 lb and a 1.8% reduction in body weight from baseline.”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Bar%20chart%20shows%20the%20percent%20change%20in%20body%20weight%20by,1.8%25%20reduction%20in%20body%20weight%20from%20baseline.)

On the page, select: Show description

> “Study limitations: This was a post-hoc subgroup analysis not adjusted for type I error. Menopausal status was not systematically collected during the clinical trials and was retroactively assigned. Due to the potential for bias introduced by these limitations, these findings should be interpreted with caution.<sup>9</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Study%20limitations%3A%20This%20was%20a%20post%2Dhoc,findings%20should%20be%20interpreted%20with)

> “The dataset was derived from randomized female participants, and only participants with non-missing baseline values were included. Data are model-based estimates (MBE) assessed using analysis of covariance (ANCOVA) according to the treatment-regimen estimand.<sup>9</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=The%20dataset%20was%20derived%20from,%28ANCOVA%29%20according%20to%20the%20treatment%2Dregimen)

> “Menopausal stage was determined based on age and clinical criteria. Patients were classified as pre-menopausal if aged <45 years with no clinical indication of menopause. Patients were classified as peri-menopausal if aged ≤54 years with a diagnosis of menopausal symptoms or clinical suspicion of menopause not meeting post-menopausal criteria, or if aged 45-54 years with no clinical evidence of menopause. Patients were classified as post-menopausal if aged ≥40 years with documented medical history of menopause, or follicle-stimulating hormone (FSH) ≥40 mIU/mL without hormone replacement therapy, or aged ≥55 years.<sup>8</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Menopausal%20stage%20was%20determined%20based,replacement%20therapy%2C%20or%20aged%20%E2%89%A555)

> “This trial was done using an investigational formulation of orforglipron at dosages equivalent to once-daily Foundayo.<sup>1</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=This%20trial%20was%20done%20using%20an%20investigational%20formulation%20of%20orforglipron%20at%20dosages%20equivalent%20to%20once%2Ddaily%20Foundayo.1,-Studied%20in%20adults%20with%20obesity%20%28BMI%20%E2%89%A530%20kg%2Fm%C2%B2%29%2C)

Note: The clinical data page labels this an ATTAIN-1 post-hoc subgroup analysis; the conference presentation it cites (Ciudin et al., ADA 2026) is titled as an analysis from ATTAIN-1 and ATTAIN-2. The page gives no difference from placebo, confidence interval, or p-value.

<a id="foundayo-age-65-subgroup"></a>

### How much weight did adults 65 and older lose on Foundayo (ATTAIN-1)?

Applies to: Adults with obesity, or with overweight and at least one weight-related comorbid condition, without type 2 diabetes (ATTAIN-1; Trial 1 in the Prescribing Information)

> “Mean percentage weight reductions were 7.5% with the 5.5 mg dose, 9.3% with the 9 mg dose, and 11.4% with the 17.2 mg dose, compared with a 1.7% reduction with placebo<sup>3</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Mean%20percentage%20weight%20reductions%20were,with%20a%201.7%25%20reduction%20with)

> “Bar chart shows the percent change in body weight from baseline at 72 weeks for patients aged 65 years and older treated with Foundayo 5.5 mg, 9 mg, and 17.2 mg, and placebo. There were 40, 51, 46, and 59 total adults given Foundayo 5.5 mg, 9 mg, and 17.2, and placebo, respectively. The percent change in body weight at 72 weeks was -7.5% for Foundayo 5.5 mg, -9.3% for Foundayo 9 mg, -11.4% for Foundayo 17.2 mg, and -1.7% for placebo. Mean baseline body weight was 212.2 lb for Foundayo 5.5 mg, 210.2 lb for Foundayo 9 mg, 206.7 lb for Foundayo 17.2 mg, and 208.3 lb for placebo.”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Bar%20chart%20shows%20the%20percent%20change%20in%20body%20weight%20from%20baseline%20at%2072%20weeks%20for%20patients%20aged%2065%20years%20and%20older%20treated%20with%20Foundayo%205.5%20mg%2C%209%20mg%2C%20and%2017.2%20mg%2C%20and%20placebo.%20There%20were%2040%2C%2051%2C%2046%2C%20and%2059%20total%20adults%20given%20Foundayo%205.5%20mg%2C%209%20mg%2C%20and%2017.2%2C%20and%20placebo%2C%20respectively.%20The%20percent%20change%20in%20body%20weight%20at%2072%20weeks%20was%20%2D7.5%25%20for%20Foundayo%205.5%20mg%2C%20%2D9.3%25%20for%20Foundayo%209%20mg%2C%20%2D11.4%25%20for%20Foundayo%2017.2%20mg%2C%20and%20%2D1.7%25%20for%20placebo.%20Mean%20baseline%20body%20weight%20was%20212.2%20lb%20for%20Foundayo%205.5%20mg%2C%20210.2%20lb%20for%20Foundayo%209%20mg%2C%20206.7%20lb%20for%20Foundayo%2017.2%20mg%2C%20and%20208.3%20lb%20for%20placebo.,-Treatment%20and%20placebo)

On the page, select: Show description

> “Study Limitations: This was a prespecified sub-group analysis not adjusted for type I error. Sub-group sample sizes are limited; therefore, findings should be interpreted with caution. The dataset was derived from the mITT population, and only participants with non-missing baseline value were included in analysis. Missing values were imputed using observed data and MMRM from the same treatment group.<sup>3</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Study%20Limitations%3A%20This%20was%20a%20prespecified%20sub%2Dgroup,MMRM%20from%20the%20same%20treatment)

> “This trial was done using an investigational formulation of orforglipron at dosages equivalent to once-daily Foundayo.<sup>1</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=younger%20adult%20patients.1%2C3%2A-,This%20trial%20was%20done%20using%20an%20investigational%20formulation%20of%20orforglipron,dosages%20equivalent%20to%20once%2Ddaily%20Foundayo.1)

## Related pages
- [Medical information: Foundayo (orforglipron): Chronic weight management](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management)
- [Indication](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/safety)
- [Specific populations](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/access-and-coverage)
